Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

MannKind Corporation receives approval from FDA Advisory Committee for new insulin control

 (Image source: brandigg.de)

Shares of MannKind Corporation (NASDAQ:MNKD) are soaring in early trading after the Advisory Committee of the FDA recommended the approval of MannKind’s insulin novel inhaler AFREZZA for public marketing. AFREZZA is highly effective in adult patients with type 1 or type 2 diabetes. In addition, the inhaler is fast acting with peak insulin levels revealed within a matter of 12 to 15 minutes. If approved for market, AFREZZA would be fastest mealtime insulin device in the market.